

Process development for GMP production of LV genetically modified primary cells

Dr. Alessandra Gatti Cell Process Development Manager

GENE AND CELL THERAPY

June 23<sup>th</sup>, 2020

Leading the way in Cell & Gene therapy



#### Disclaimer

This document may contain forward-looking statements that reflect the current views of the Company on future events based on information available as of today's date. Forecasts and estimates are generally identified by words such as "possible", "should", "forecast", "expected", "estimated", "believe", "intend", "plan", "objective" or by the negative form of these expressions or other variations thereof or by the use of comparable terminology. Although the Company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties that are beyond Managers' control, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those projected in the forward-looking statements. The Company assumes no obligation to publicly update and revise forecasts and estimates following the availability of new information, future events or other factors, without prejudice to compliance with applicable laws. All subsequent forecasts and estimates, whether oral or written, attributable to the Company or any persons acting on its behalf, are expressly gualified, in their entirety, by these cautionary statements. This document does not constitute an offer or invitation to subscribe for or purchase any securities of MolMed S.p.A The official manager responsible for preparing the Company's financial reports, Salvatore Calabrese, herewith attests, pursuant to Article 154-bis, paragraph 2 of the Legislative Decree 58/1998 ("Testo Unico della Finanza"), that the accounting disclosure contained in this press release matches documentary evidence, corporate books, and accounting records.



## Agenda

- 1. Company Overview
- 2. How to achieve efficient transduction of HSCs
- 3. Process development and large-scale production of autologous LV CAR-T cells



## Agenda

#### 1. Company Overview

- 2. How to achieve efficient transduction of HSCs
- 3. Process development and large-scale production of autologous LV CAR-T cells



## MolMed is a pure player in the Cell&Gene arena



Focusing on **innovative cell and gene therapies** that can meet the therapeutic needs in the treatment of **tumors and rare diseases**, with a clear and solid industrial project based on **research**, **development** and **production excellence** 






**CDMO Business**, with **35+** Programs developed with our Partners

**R&D Business** on our Autologous Product **CAR-T CD44v6** 

GENE AND CELL THERAPY / Dr. Alessandra Gatti




CDMO business experience in manufacturing of vector and modified cells



GENE AND CELL THERAPY / Dr. Alessandra Gatti

MOLMED

# Current manufacturing platforms



## Excellent GMP capacity with more than 230 scientists and support staff

#### Milan Site (San Raffaele)

- **1,500 SQM** (16,000 SQF) and **6 grade B/C suites**
- 2003: Authorized GMP manufacturing facility for Clinical programs
- 2015: Authorized GMP manufacturing facility for Commercial products






#### **Bresso Site**

- **3,300 SQM** (36,000 SQF) and **>20 Grade B/C suites**
- Authorized for **GMP manufacturing** and **QC** for the production of **clinical** and **commercial** products
- **Recently authorized Stream#2**, for further services and new collaborations



## Development and manufacturing partners in EU and US geographies



35+ Programs currently in Development and GMP
2 Commercial Cell-Engineered Products in EU
2 Commercial Viral Vectors in EU
15+ Cell-Engineering programs for EU&US
20+ Viral Vectors programs for EU&US

#### **Track Record**

**300+** Treated Patients (autologous)

**220+** Manufactured GMP Vectors

**30+** C&G Clinical Trials Supplied in EU&US

MOLMED

8+ International Service Partners

#### Strenghts of MolMed CDMO

High **GMP manufacturing Capacity** thanks to new facility in Milan area

25yrs **Experience** in proprietary projects now available for CDMO collaborations

Recognized **Flexibility** in accommodating Partners' requests

Regulator Faciliti Developmen

**160 QC tests internalized,** ensuring reduction in time and cost

> Ready **Proprietary Processes** for vectors and cells engineering

1<sup>st</sup> Approved Facility for C&G therapies




## Agenda

- 1. Company Overview
- 2. How to achieve efficient transduction of HSCs
- 3. Process development and large-scale production of autologous LV CAR-T cells



## *How to achieve efficient transduction of HSCs*




High-efficiency transduction with minimal manipulation of HSCs remains a crucial point to improve




#### Optimize manufacturing process

























#### Optimized LV CD34+ transduction process: Results




**HSC sub-population markers** 

CD34+ cells






Viability %



Mean of 4 large scale experiments (3 starting from mPB and 1 from BM)



#### Optimized LV CD34+ transduction process: Results



**Transduction Efficiency** 

Mean of 4 large scale experiments (3 starting from mPB and 1 from BM)



GENE AND CELL THERAPY / Dr. Alessandra Gatti

#### Optimized LV CD34+ transduction process: Conclusions

#### **Process features**

- Adaptable MOI and 2<sup>nd</sup> hit of transduction optional
- Improved culture conditions
- Avoid the use of transduction enhancers
- New chemically defined medium and No animal derived components

 Cost reduction
 Increased maintenance of stem potential

High-efficiency transduction

No IP restrictionsCost reduction

 Increased Safety
 Increased maintenance of stem potential






**Benefits** 

## Agenda

- 1. Company Overview
- 2. How to achieve efficient transduction of HSCs
- 3. Process development and large-scale production of autologous LV CAR-T cells




#### CAR-T Cell Therapy: How does it work?






#### CAR-T Cell Therapy: Optimization and Scale-up?






#### LV CAR-T Cell Process: Overview

Autologous/ Compatible Donor Therapy






#### LV CAR-T Cell Process: Results




Mean of 5 large scale experiments from healthy donors PBMC transduced with CD44v6.CAR LV



BAG

G-REX


VCN






#### GENE AND CELL THERAPY / Dr. Alessandra Gatti

#### LV CAR-T Cell Process: Results





T cells activation markers

G-REX

BAG

Mean of 5 large scale experiments from healthy donors PBMC transduced with CD44v6.CAR LV



#### LV CAR-T Cell Process: Conclusions

Cost saving
 Reduced consumption of reagents
 No use of adjuvants

# Short window of expansion Increased fold expansion Maintainance of naïve T cells

# ✓ Flexibility

Different sources of starting material
 Different process steps options

Open or closed system

#### ✓ Safe

Suitable for closed and semi automated systems

- (e.g. CliniMacs Prodigy and LOVO instruments)
  - No animal-derived components
  - Reduced manipulation volumes





## Thank you for your attention!

#### Dr. Alessandra Gatti

Cell Process Development Manager

e-mail: Alessandra.Gatti@molmed.com

MolMed S.p.A.

GENE AND CELL THERAPY / Dr. Alessandra Gatti

